124 results about "Anticoagulation Agents" patented technology

The invention provides an abnormal blood sampling inspection data evaluation processing method and system of a blood sampling system. Wherein the diffusion track dynamic state of an anticoagulant-blood contact surface in a blood sampling tube is tracked in real time, dielectric response waveform distortion characteristics on the two sides are synchronously collected through a capacitance sensor array, and diffusion form parameters are generated; curvature sudden change is analyzed to trigger an acoustic fluid device to modulate audio frequency and flow velocity, and a composite disturbance field is formed; performing capacitance axial scanning on the disturbed mixed fluid, extracting phase angle offset and gradient abrupt change point coordinates, and constructing a dielectric anomaly three-dimensional map; matching a standard dielectric model, positioning a coordinate set of a concentration gradient imbalance area and a coordinate set of an eddy current attenuation area, and generating an anticoagulant abnormal index and a mixed defect matrix in combination with phase angle offset difference; and establishing a data anomaly degree evaluation function based on the anomaly index and the defect matrix, dynamically associating a clinical error threshold, and outputting a test evaluation result. According to the invention, anticoagulant diffusion can be monitored in real time, and the mixing quality error can be accurately evaluated.

The invention provides a sample pretreatment automation method for flow cytometry, and belongs to the technical field of sample pretreatment for flow cytometry. A biological sample to be detected is collected and placed in a collection tube containing an EDTA-K2 anticoagulant for pretreatment; an automatic pipetting system is used for carrying out incubation reaction on an anticoagulant whole blood sample and an intelligent matching fluorescence labeling antibody mixed solution, and a double-layer game optimization verification system is used for verifying the rationality of an antibody adding proportion and reaction condition parameters; carrying out fluorescence characteristic readability index prediction on the incubated cell suspension by adopting an intelligent dilution parameter regulator model, dynamically adjusting hemolysis parameters and suspension conditions, and adding 1 * hemolysin working solution by using an automatic liquid adding device to carry out hemolysis treatment so as to finish pretreatment; the technical problems that in the pretreatment process of flow cytometry detection samples, parameters are often based on artificial experience, and the reproducibility and standardization degree of detection results are insufficient are solved.

Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

The invention discloses a preparation method and application of autologous fibrin glue, and belongs to the field of biomedical materials. The preparation method comprises the following five steps: collecting autologous venous blood, adding a sodium citrate anticoagulant with the volume ratio of 1: (8-12), and storing at 4-6 DEG C for not more than 2 hours; performing step-by-step centrifugation at the speed of 1500 to 2000 r / min and the speed of 3500 to 4000 r / min to obtain a fibrinogen concentrate; the thrombin-calcium chloride activation solution A and the tranexamic acid activation solution B are mixed according to the ratio of 1: (2-3) to form a composite activation system; mixing the two components according to a mass ratio of 1: (0.8-1.2), and reacting at 25-37 DEG C for 3-5 minutes to form colloid; and pre-freezing at-40 to-60 DEG C, performing vacuum freeze-drying, and storing at 4-8 DEG C. During application, the colloid can be coated on an operation wound surface after being redissolved, or mixed with a growth factor to prepare a dressing for covering a chronic wound surface. The colloid is high in purity, stable in coagulation time, long in storage period, suitable for scenes such as surgical hemostasis and the like, and high in clinical value.

The invention discloses blood component single sampling equipment capable of monitoring in real time in the field of blood treatment equipment. The equipment comprises a blood sampling module, a centrifugal separation module, a component collection module and an anticoagulant conveying module, and further integrates a multi-dimensional real-time monitoring system and a closed-loop self-adaptive regulation and control module. The multi-dimensional real-time monitoring system comprises an online micro-fluidic component detection unit, a physiological parameter monitoring unit and an equipment operation monitoring unit, can realize real-time online detection of blood component purity, cell activity and pollutant residue in the separation process, and synchronously monitors circulation physiological parameters of a blood donor and an equipment operation state at the same time; the closed-loop self-adaptive regulation and control module can dynamically adjust parameters such as the centrifugal rotating speed, the fluid pump speed and the anticoagulant ratio according to real-time monitoring data, and precise closed-loop control over the separation process is achieved. The quality stability of blood single-sampling components can be remarkably improved, meanwhile, the operation risk is greatly reduced, and the method is suitable for clinical blood component single-sampling and preparation scenes.

In various embodiments, disclosed herein are methods of assessing therapeutic efficacy of an anticoagulant. Preferably, the method comprising providing a blood sample; perfusing the blood sample over a surface coated with collagen or immobilized rTF; measuring platelet aggregation and fibrin deposition on the surface coated with collagen or immobilized rTF; and assessing therapeutic efficacy of the anticoagulant based on the volume of platelet aggregates and / or deposited fibrin.

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting / coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and / or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

The present invention discloses a modified polyimide hollow fiber membrane. The hollow fiber membrane comprises a polysulfone / polyethersulfone matrix component and a modified polyimide hydrophobic polymer containing 30% to 100% of the matrix component by weight. The modified polyimide hydrophobic polymer is prepared by mixing water, a strongly polar solvent, an alkaline catalyst, and a polyimide resin at 80 to 120°C for a partial hydrolysis reaction for 5 to 10 hours. After the solution is cooled, the pH is adjusted to 1 to 3 to remove water. A polyamine is first added and stirred for 2 to 4 hours. A carboxyl-containing anticoagulant is then added and a grafting reaction is carried out for 12 to 48 hours to obtain the modified polyimide hydrophobic polymer. The hollow fiber membrane prepared by the present invention has a good ultrafiltration coefficient, significantly improved hydrophilicity, effectively reduces the deposition of prothrombin and fibrin, and significantly improves the anticoagulant effect, making it suitable for use as a blood purification material.

To provide a factor Xa reagent.SOLUTION: Exemplary compositions include Factor Xa, a substrate, one or more guanidine derivatives, and in some cases heparin. An exemplary method of detecting an anticoagulant in a sample includes combining or contacting a composition with a sample and measuring factor Xa activity based on substrate status. The composition modulates the activity of factor Xa in the sample, and the modulation includes a reduction in the rate of clotting of the sample caused by factor Xa. The presence of an anticoagulant is based on the activity of factor Xa.SELECTED DRAWING: None

The application discloses a kind of plasma collection systems, belongs to the field of plasma collection.A kind of plasma collection system, including equipment box, still including separation box being fixed in the top of equipment box, separation box is provided with the filter part of separating blood and plasma in, wherein, the top of separation box is provided with liquid storage ring, drop adding part for adding anticoagulant into separation box is set on the liquid storage ring;Refrigerator is fixed on the equipment box, refrigeration bin is opened in the side wall of equipment box, and the output end of refrigerator is communicated with the inner cavity of refrigeration bin;The repulsion of piston plate and magnetic plate makes the air pressure in separation box continuously reduce, so that blood moves more quickly into separation box, effectively improves blood collection efficiency;And cooperate with rotary shaft to drive filter hopper to rotate, so that filter hopper generates centrifugal force effect, so that plasma component in blood more quickly and effectively passes through filter membrane, effectively improves separation effect.

The invention belongs to the technical field of biological medicine, and relates to an anticoagulant, in particular to an anticoagulant for a high-precision animal blood cell analyzer and application of the anticoagulant in leukocyte classification. The anticoagulant comprises a buffer and anticoagulation matrix component and an active component, wherein in every 100 mL of the anticoagulant, the buffer and anticoagulation matrix component formula comprises 1.5 to 2 g of citrate, 0.3 to 0.5 g of citric acid and 0.15 to 0.20 g of EDTA-K2 (Ethylene Diamine Tetraacetic Acid), and the active components comprise 0.08 to 0.10 g of low molecular weight enzymolysis carboxymethyl chitosan, 1.0 to 1.2 g of hydroxypropyl-beta-cyclodextrin, 10 to 15 mg of dipyridamole and 8 to 10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and leukocyte morphological deformation, realizes accurate identification in leukocyte five-classification, has a classification accuracy rate of 98%, and is suitable for veterinary clinical hematology examination and animal epidemic disease monitoring.

To provide a blood collection container capable of reducing the amount of leukocytes mixed into plasma even when blood is centrifuged several days after collection. The blood collection container according to the present invention comprises a blood collection container body, a plasma separation material contained in the blood collection container body, and an aqueous solution contained in the blood collection container body, wherein the aqueous solution contains an anticoagulant and a lithium salt different from the anticoagulant.

Disposable cartridges and methods for detecting and classifying an anticoagulant at a therapeutically relevant amount or higher in a patient. The cartridges include a plurality of chambers, as well as fluidic couplings between chambers. Calcium chloride, Russel Viper Venom (RVV), an ecarin reagent, a Factor Xa reagent, protamine, kaolin, tissue factor, and combinations thereof may be included in a given chamber.

The application relates to the technical field of blood cell separation machines, in particular to a blood cell separation machine device for hematology nursing, which comprises a stirring mechanism, a feeding mechanism, a drawing mechanism, a centrifugal mechanism and a separation mechanism. The upper end of the stirring mechanism is provided with the feeding mechanism, the lower end of the feeding mechanism is provided with the drawing mechanism, the lower end of the drawing mechanism is provided with the centrifugal mechanism, and the centrifugal mechanism is provided with the separation mechanism at one end. The rotating stirring blade can uniformly mix blood and anticoagulant, preventing the blood from coagulating before centrifugation. The second sliding block and the first connecting pipe are in sliding cooperation, so that the anticoagulant can be automatically and quantitatively added into the cylinder. The second sleeve can draw the blood in the cylinder to the test tube when the first motor stops rotating. The sliding pipe and the second fixed block can quickly take out the separated blood plasma. The third sliding block can be pulled outward to take out the remaining blood cells conveniently and quickly.

Provided herein are devices, systems, methods, and compositions, including compositions for coupling to a surface of an implantable article, the compositions comprising an anticoagulant comprising a direct factor Xa inhibitor and at least one of (a) an antiplatelet drug, (b) an anticoagulant comprising a direct factor IIa inhibitor, and (c) an anti-inflammatory drug comprising colchicine.

The invention belongs to the technical field of clinical medicine, and relates to a method for extracting autologous platelet-rich plasma, which comprises the following steps of: adding an anticoagulant into an injector I in advance, then extracting autoblood, uniformly mixing for 3-4 times back and forth by virtue of an injector II, then centrifuging for 10 minutes at the speed of 1,500 revolutions per minute, sucking the platelet-rich plasma in the injector I by virtue of an injector III, and extracting the platelet-rich plasma in the injector II by virtue of an injector III. And centrifuging again, and discarding the supernatant by using an injector IV to obtain a high-concentration PRP finished product. According to the extraction method, in the extraction process, blood is uniformly mixed for 3-4 times back and forth between an injector I and an injector II, and the blood is centrifuged for 10 minutes at the speed of 1500 r / min in the first centrifugation process, so that the platelet concentration in the finally extracted PRP is remarkably improved compared with the platelet concentration in peripheral blood; the red blood cells reach the quality control target, the white blood cells are obviously reduced, and a set of standardized autologous platelet-rich plasma clinical extraction method which is simple in extraction device, low in consumable cost, simple to operate and high in extraction concentration is formed.

The present invention consists of a digital, always-online computer system designed to optimize perioperative safety through the automated integration of clinical and laboratory parameters. Unlike conventional medical calculators, this system implements a reactive logic engine that simultaneously calculates glomerular filtration rate (CKD-EPI 2021) and scores multiple risk scales (Goldman, LEE, ASA, CHA2DS2-VASc, HAS-BLED) without duplicate data entry. The system includes a drug reconciliation algorithm that cross-references the bleeding risk of the surgical procedure with the patient's renal function, generating accurate recommendations for discontinuing or continuing high-risk medications (anticoagulants, antiplatelet agents, SGLT2 inhibitors) based on current clinical evidence.

The invention discloses a method for extracting immune globulin in pig blood and application of the method, and relates to the technical field of fresh pig blood extraction.The method comprises the following steps that S1, after fresh pig blood and an anticoagulant are evenly mixed, low-temperature standing and centrifugation are conducted, plasma liquid is separated out and stored, and the plasma liquid is obtained; s2, extracting the plasma liquid through three times of ethanol reaction to obtain an immune globulin crude product; s3, carrying out three-stage purification on the immune globulin crude product, namely precipitation treatment, hollow fiber ultrafiltration column dealcoholization treatment and affinity chromatography treatment, and finally, dialyzing and freeze-drying to obtain an immune globulin IgG finished product. According to the method for extracting the immune globulin in the pig blood, the extraction rate and the purity of the immune globulin IgG can be effectively improved.

The invention relates to the field of blood detection reagents, in particular to a blood free DNA stabilizer and application thereof. Every 100 ml of the blood free DNA stabilizer comprises 0.5-5 g of a buffer agent, 2-20 g of an aldehyde fixing agent, 15-20 g of an anticoagulant, 10-50 g of a cell stabilizer, 2.5-12.5 g of a nuclease inhibitor, and the balance of ultrapure water. The pH value of the blood free DNA stabilizer is 6.8 to 7.8; the cell stabilizer is selected from one or two or more than two of polysucrose-50, polysucrose-70, polysucrose-400, polyethylene glycol-4000, polyethylene glycol-6000, polyethylene glycol-8000 and glycine betaine. Preferably, the cell stabilizer is selected from polysucrose-70, and every 100 ml of the blood free DNA stabilizer contains 10 g of polysucrose-70. The stabilizer provided by the invention is low in toxicity and low in cost, and can maintain free DNA stability and inhibit blood cell genome release at normal temperature for 10 days, so that the storage cost and the transportation cost of a blood sample are effectively reduced, and the detection accuracy of the blood free DNA is improved.

The embodiments herein provide hemostatic compositions, methods, and kits comprising composite polymer particles. Upon contact with blood or other physiological fluids, the composite particles adsorb fluid and aggregate into a shape-retentive mass that halts bleeding. In certain embodiments, the particles comprise polymers of 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, or combinations thereof. The particles may be used alone or blended with additional hemostatic agents. Methods of inducing hemostasis are provided for diffuse oozing, or surgical, mucosal, organ surface, fragile tissue or traumatic bleeding, including in patients receiving anticoagulant or antiplatelet therapy. Kits comprising sterile packages of composite particles, optionally with applicators, substrates, or sprays, are disclosed. The compositions exhibit intrinsic hemostatic activity and synergistically enhance the performance of conventional hemostats, achieving rapid clotting. After hemostasis is achieved, the compositions remain in situ as a conforming protective layer, reducing the need for additional covering materials and decreasing risk of re-bleeding.

Disclosed are techniques for delaying initiation of coagulation and suppressing fibrin formation. The disclosed techniques may include providing a percutaneous blood pump that may include a metal or ceramic surface (such as a surface of a shaft, bearing, rotor, stator, etc.) that has been modified with a bifunctional modifier. The modified surface may be within a motor section and / or pump section of the blood pump. The modified surface may be configured to interact with blood. When blood is allowed to interact with the modified surface, a desirable microenvironment may be formed. The bifunctional modifier may be a functionalized aminosilane, a functionalized aminosiloxane, and / or a functionalized silanetriol. The blood pump may be configured to have a purge fluid pass through at least a portion of the motor section and / or the pump section. The purge fluid may be free of anticoagulants.

The invention discloses a blood sampler, and relates to the technical field of blood sampling. Comprising a blood collection piece, a flow guide piece is installed in the blood collection piece, and the flow guide piece is used for guiding blood to the bottom of the blood collection piece; the blood collection piece is sleeved with a lifting adjusting piece; a lifting isolation piece is mounted in the blood collection piece; the lifting isolation piece magnetically attracts the lifting adjusting piece; a puncture sampling piece is mounted on the blood collection piece; an anticoagulant is conveniently drained to the inner side of the drainage tube by utilizing the lifting isolation piece, and the flow guide piece can be used for draining blood, so that the blood can be conveniently and directly discharged from an anticoagulant solvent at the bottom of the blood collection tube during collection, and the anticoagulant effect is ensured; the problems that according to an existing blood sampler, direct anticoagulation drainage to a solvent is not convenient, clear liquid is not convenient to isolate, protect and separate, and butt joint is tedious through manual single-hand operation are solved.

The invention relates to a composition for stabilizing a human prothrombin complex and application of the composition. The composition comprises an anticoagulant and a protective agent, the anticoagulant is heparin and / or a pharmaceutically acceptable salt thereof; the protective agent is selected from arginine and / or histidine and one or more of their respective pharmaceutically acceptable salts, and the ratio of the anticoagulant to the protective agent is (4.5-9.5) IU: (0.02-0.04) g. The activity of FII, FVII, FIX and FX of the prothrombin complex preparation prepared by adopting the composition for stabilizing the human prothrombin complex provided by the invention is not obviously reduced even under the condition of high temperature (40 + / -2 DEG C), and the activity of the FII, the FVII, the FIX and the FX is not obviously reduced after the prothrombin complex preparation is stored at the high temperature for at least 24 months. The biological activity index of the prothrombin complex preparation still meets the clinical use standard.

The present invention provides a method for preventing, treating or alleviating bleeding caused by an anticoagulant using an anticoagulant reversal agent. The anticoagulant reversal agent has a structure as shown in formula I, can well inhibit bleeding complications caused by anticoagulants, for example, bleeding complications caused by anticoagulants such as an Xa factor inhibitor, and has the characteristics of broad spectrum and high efficiency.

Disclosed are techniques for delaying initiation of coagulation and suppressing fibrin formation. The disclosed techniques may include providing a percutaneous blood pump that may include a metal or ceramic surface (such as a surface of a shaft, bearing, rotor, stator, etc.) that has been modified with a bifunctional modifier. The modified surface may be within a motor section and / or pump section of the blood pump. The modified surface may be configured to interact with blood. When blood is allowed to interact with the modified surface, a desirable microenvironment may be formed. The bifunctional modifier may be a functionalized aminosilane, a functionalized aminosiloxane, and / or a functionalized silanetriol. The blood pump may be configured to have a purge fluid pass through at least a portion of the motor section and / or the pump section. The purge fluid may be free of anticoagulants.

The invention relates to a hemoperfusion device and a controller for measuring a blood coagulation state, the hemoperfusion device is connected between an artery side blood loop and a vein side blood loop, and the hemoperfusion device comprises an adsorption column, the adsorption column is provided with at least two adsorption areas which are oppositely arranged and allow to-be-purified blood to be in contact with the adsorbent, and an observation area which is formed between the at least two adsorption areas and allows the to-be-purified blood to independently flow; wherein the at least two adsorption areas are arranged at intervals through a fiber membrane or a baffle structure with filter holes, so that an observation area which is not filled or not completely filled with adsorbent particles is formed between the at least two adsorption areas. The current blood coagulation state progress degree of the hemoperfusion device can be determined according to the blood flowing information of the to-be-purified blood in the observation area, and the working states of the blood pumping device, the anticoagulant pumping device and / or the heating device in the blood purification loop can be selectively adjusted according to the current blood coagulation state.

Provided herein are compositions comprising (1) a citrate-based anticoagulant (AC), an aldehyde releaser (AR), a calcium channel blocker, and a sodium channel blocker and (2) a citrate-based anticoagulant (AC), an aldehyde releaser (AR), and a sodium channel blocker, and uses of such compositions for stabilizing components in a blood sample.

The utility model relates to a separation device for injectable concentrated growth factors, which makes up the defects of the prior art in the preparation of injectable CGF, such as incapability of separation caused by blood coagulation in the preparation process, and incapability of slow release of growth factors due to inhibition of formation of a fibrous protein scaffold by using an anticoagulant. After blood sampling, blood is injected into the lower cavity of the separation device, PPP, CGF and RBC are obtained through a specific centrifugal program, the first piston assembly is pushed to enable the PPP on the upper layer to enter the upper cavity, the upper cover body is moved downwards to enable the third barrel to be communicated with the lower cavity, the first piston assembly is moved upwards to enable the CGF to enter the third barrel, and separation can be completed. During separation, only the piston needs to be pushed up and the upper cover body needs to be moved downwards, operation is simple, samples do not need to be transferred, the separation process is isolated from the outside, and safety is high; the prepared CGF can continuously and slowly release various autologous growth factors, and is beneficial to playing a continuous role in a long-term tissue repair process.

The invention provides a preparation method of a canine autologous platelet-rich fibrous protein membrane, which comprises the following steps of: collecting canine autologous vein blood by using a vacuum blood collection tube with a preset anticoagulant, centrifuging, discarding supernatant, centrifuging again, discarding lower erythrocytes, and collecting the canine autologous platelet-rich fibrous protein membrane. And placing the obtained dog autologous platelet-rich fibrous protein gel between double stainless steel grids, and pressing to obtain the dog autologous platelet-rich fibrous protein membrane. The invention also provides an application of the prepared autologous platelet-rich fibrin membrane for dogs, wherein the autologous platelet-rich fibrin membrane is used for preparing drugs for wound repair. According to the invention, the autologous platelet-rich fibrin therapy is used for preparing the drug for repairing the dog wound for the first time, and through a triple mechanism of replacing antibiotics by autoimmune regulation, promoting healing by sequential release of growth factors and a zero-allergen biological scaffold, the healing period is shortened while the public health risk is avoided, and the healing effect is improved. The method is an innovative scheme with safety, effectiveness and sustainability.